Back to top
more

Myomo (MYO)

(Delayed Data from AMEX)

$4.90 USD

4.90
233,816

+0.09 (1.87%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $4.87 -0.03 (-0.61%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo (MYO) delivered earnings and revenue surprises of 25% and 15.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0% and 3.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

by Zacks Equity Research

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Myomo, Inc. (MYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 26.67% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 34.09% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 6.67% and 4.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

What Makes Myomo, Inc. (MYO) a New Strong Buy Stock

by Zacks Equity Research

Myomo, Inc. (MYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Myomo, Inc. (MYO) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 25.81% and 51.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?